BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1534-4681
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
BRAF Mutation in Papillary Thyroid Microcarcinoma: The Promise of Better Risk Management ; volume:16 ; number:4 ; day:22 ; month:1 ; year:2009 ; pages:801-803 ; date:4.2009
Annals of surgical oncology ; 16, Heft 4 (22.1.2009), 801-803, 4.2009
- Creator
-
Xing, Mingzhao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1245/s10434-008-0298-z
- URN
-
urn:nbn:de:101:1-2021081620301707013859
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Xing, Mingzhao
- SpringerLink (Online service)
Other Objects (12)
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study
Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
BRAFV600E and BRAF-WT Specific Antitumor Immunity in Papillary Thyroid Cancer
Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
Mcl-1 mediates intrinsic resistance to RAF inhibitors in mutant BRAF papillary thyroid carcinoma
BRAF V600E mutation is associated with aggressive features in papillary thyroid carcinomas ≤ 1.5 cm
False-negative BRAF V600E mutation results on fine-needle aspiration cytology of papillary thyroid carcinoma
Shifted termination assay (STA) fragment analysis to detect BRAF V600 mutations in papillary thyroid carcinomas
Silencing FOXP2 reverses vemurafenib resistance in BRAF V600E mutant papillary thyroid cancer and melanoma cells
High-density microarray expression profiling in conventional papillary thyroid carcinomas with versus without a BRAF mutation
BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma
Prognostic Significance of Various Clinicopathologic Parameters and BRAF V600E Mutation in Papillary Thyroid Microcarcinoma—An Observational Study